Deepak Shenoy-backed Capitalmind Flexi Cap Fund exited 11 stocks, including Vedanta and Vedanta Oil and Gas, and added nine stocks, includi...

Strides Pharma Science shares rise sharply on Thursday after the USFDA issued an Establishment Inspection Report (EIR) for its Bengaluru fa...

Credent Connect N Care shares made a blockbuster debut on the NSE SME platform, listing at a 90% premium over the IPO price. The Rs 93.90-c...

In July, Helios Mid Cap Fund boosted its investments by increasing its stake in Swiggy among twenty other stocks. Notably, the fund expande...

Invesco Mutual Fund has launched a new open-ended equity scheme. This fund will invest in India's evolving pharma and healthcare sectors. I...

July was a busy month for HDFC Mutual Fund, which ramped up its investments by increasing its stakes in about 422 stocks. Simultaneously, t...

Lupin received USFDA approval for generic Pitolisant Tablets, strengthening its US portfolio and specialty generics presence. Shares remain...

Market breadth is important, especially at this point of time. It is a better indicator of both underlying sentiment and what is likely in ...

Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...

For the chemicals sector, it all depends on a transformation that is still unfolding and will take years to play out. Backward-integration ...

The heatwaves pummelling Europe this summer will have costly impacts on industries ranging from agriculture to tourism -- but that hasn't s...

Quant Mid Cap Fund exited Anthem Biosciences and Lenskart Solutions in July, while adding five new stocks including Cochin Shipyard, UPL an...

Japan’s Nikkei 225 rose nearly 1% on Friday and was on track for a strong weekly gain, supported by softer-than-expected US producer prices...

In July, fund managers recalibrated their blue-chip stock portfolios, focusing on select sectors like IT, automotive, and pharmaceuticals f...

The Bombay High Court has told the Tukaram Mundhe-led Maharashtra FDA to use its powers judiciously after Cadila Pharmaceuticals challenged...

Zydus Lifesciences reported a significant year-on-year decline of thirty-six percent in net profit for the first quarter, despite a robust ...

For Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...